No Data
No Data
sh pharma (601607.SH) will distribute A-share cash dividends on September 24, with a dividend of 0.08 yuan per share.
sh pharma (601607.SH) announced that the company will distribute the 2024 half-yearly report on September 24, 2024...
Sh Pharma(02607): Implementation of H-share shareholder shareholding plan completed.
Sh Pharma (02607) announced that Shanghai Pharma Group Co., Ltd. (hereinafter referred to as the "Company") acquired 20...
Sh pharma: Shanghai Industrial Holding Group has completed its shareholding plan, with a total shareholding of 7.8996 million hong kong-listed shares.
Shanghai Pharma announced that as of September 10, 2024, the Hong Kong Stock Exchange has closed, and the SR Group's plan to increase its shareholding in the company's listed H shares has been completed. During the shareholding period, the SR Group increased its shareholding in the company's H shares through SR International by a total of 7,899,600 shares.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
SHANGHAI PHARMACEU To Go Ex-Dividend On September 19th, 2024 With 0.0562 USD Dividend Per Share
No Data
No Data